<DOC>
	<DOCNO>NCT00829413</DOCNO>
	<brief_summary>The purpose study demonstrate Sensitivity Specificity SonoVue®-enhanced ultrasound superior unenhanced ultrasound characterization benign versus malignant FLLs use final diagnosis base histology combine imaging ( CE-CT and/or CE MRI ) /clinical data truth standard .</brief_summary>
	<brief_title>SonoVue®-Enhanced Ultrasound ( US ) Versus Unenhanced US Focal Liver Lesion Characterization</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Male/female . Provides write Informed Consent willing comply protocol requirement . Is least 18 year age . Has least 1 FLL ( target lesion ) require workup characterization . Target lesion may include : Incidentally detect , In subject chronic hepatitis liver cirrhosis , In subject know history malignancy . Is schedule surgical removal biopsy target lesion 24 hour 30 day SonoVue® administration OR In case tissue biopsy indicate surgery plan , schedule perform CECT and/or CEMRI target lesion 30 day 48 hour prior 24 hour 30 day administration SonoVue® . Has acoustic window insufficient adequate ultrasound examination liver . Has FLL identify unenhanced ultrasound . Has receive schedule antineoplastic chemotherapy invasive procedure time period test procedure truth standard assessment may modify target lesion . Is receive contrast medium , within 48 hour 24 hour follow administration SonoVue® . Has previously enrol complete study . Known right left cardiac shunt , bidirectional transient . Has know allergy 1 ingredient investigational product ( sulfur hexafluoride component SonoVue® ) . Has contraindication 1 plan imaging procedure ( ultrasound , CT MRI ) , e.g. , implant , claustrophobia , inadequate medical condition etc . Has receive investigational compound within 30 day admission study . Has medical condition circumstance would significantly decrease chance obtain reliable data , achieve study objective , complete study and/or postdose followup examination . Is determined Investigator subject clinically unsuitable study . Is pregnant lactate female . Exclude possibility pregnancy : test site institution serum βHCG within 24 hour prior start SonoVue® administration , surgical history ( e.g. , tubal ligation hysterectomy ) , post menopausal minimum 1 year without menses .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>